• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    4/5/24 8:09:50 AM ET
    $AIH
    $CADL
    $ETAO
    $GOVX
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AIH alert in real time by email

    Gainers

    • Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million.
    • Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 25.93% to $8.06. The company's market cap stands at $236.5 million.
    • Etao International Co (NASDAQ:ETAO) shares moved upwards by 25.61% to $3.58. The market value of their outstanding shares is at $18.3 million.
    • Indaptus Therapeutics (NASDAQ:INDP) shares rose 11.11% to $2.5. The company's market cap stands at $21.3 million.
    • scPharmaceuticals (NASDAQ:SCPH) stock moved upwards by 10.7% to $5.69. The company's market cap stands at $205.1 million.
    • Molecular Templates (NASDAQ:MTEM) shares moved upwards by 8.33% to $1.95. The company's market cap stands at $12.8 million.

    Losers

    • Aesthetic Medical Intl (NASDAQ:AIH) stock decreased by 17.8% to $0.42 during Friday's pre-market session. The market value of their outstanding shares is at $20.0 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares declined by 8.72% to $1.78. The company's market cap stands at $4.3 million.
    • Imunon (NASDAQ:IMNN) stock fell 8.64% to $1.27. The company's market cap stands at $11.9 million.
    • Helius Medical Tech (NASDAQ:HSDT) stock fell 8.46% to $5.63. The company's market cap stands at $4.9 million.
    • MiNK Therapeutics (NASDAQ:INKT) shares decreased by 8.21% to $1.23. The market value of their outstanding shares is at $42.6 million.
    • Geovax Labs (NASDAQ:GOVX) stock decreased by 7.94% to $1.85. The market value of their outstanding shares is at $4.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $CADL
    $ETAO
    $GOVX

    CompanyDatePrice TargetRatingAnalyst
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Protara Therapeutics Inc.
    $TARA
    1/7/2026$24.00Overweight
    Piper Sandler
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    MiNK Therapeutics Inc.
    $INKT
    8/15/2025$35.00Neutral → Buy
    H.C. Wainwright
    MiNK Therapeutics Inc.
    $INKT
    7/14/2025Outperform → Mkt Perform
    William Blair
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    Protara Therapeutics Inc.
    $TARA
    4/16/2025$12.00Sector Outperform
    Scotiabank
    More analyst ratings

    $AIH
    $CADL
    $ETAO
    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

    NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at TD Cowen's 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, 2026 Time: 11:50 AM - 12:20 PM ET Webcast Link: TD Cowen / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News &

    2/24/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

    Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in patients with high-risk Non-Muscle Inva

    2/23/26 5:05:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana

    Deployment to be focused on Asia-Pacific region to capitalize on fast-growing wealth accumulation, cross-border payments, and institutional adoption of digital assetsExpansion planned to enable Solana Company to capture more value by eliminating external costs and providing compliant infrastructure for regulated institutionsStrategic buildout designed to address needs of market makers, high-frequency traders, exchanges, and traditional finance partners across the Solana ecosystem NEWTOWN, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT or the "Company") today rolled out a strategic roadmap to invest in a new low-latency cluster in Asia Pacific to drive staking and v

    2/23/26 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/19/25 4:10:10 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/16/25 4:05:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    SEC Filings

    View All

    SEC Form 8-K filed by Candel Therapeutics Inc.

    8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

    2/23/26 8:00:28 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Solana Company filed SEC Form 8-K: Other Events

    8-K - Solana Co (0001610853) (Filer)

    2/20/26 5:07:27 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Candel Therapeutics Inc.

    424B5 - Candel Therapeutics, Inc. (0001841387) (Filer)

    2/20/26 4:16:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Protara Therapeutics with a new price target

    Piper Sandler initiated coverage of Protara Therapeutics with a rating of Overweight and set a new price target of $24.00

    1/7/26 9:14:32 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Co-Chief Executive Officer Meckler Jeffrey A

    4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    2/13/26 4:15:18 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:04:50 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Nichols William Garrett

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:03:33 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

    Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

    10/11/22 1:54:57 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    Financials

    Live finance-specific insights

    View All

    TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

    Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in patients with high-risk Non-Muscle Inva

    2/23/26 5:05:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

    TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unre

    12/3/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

    NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administrat

    12/1/25 4:15:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. He pioneered major innovations in combat casualty care, transfusion medicine, and trauma systems design that saved countless lives and reshaped global health protocol

    9/29/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $CADL
    $ETAO
    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    12/17/24 4:02:03 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

    SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    11/26/24 4:11:08 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care